• Robin Mackie new President of Ideanomics Mobility, as of September 8, 2021
• Mackie will help the company to make the most out of its acquisitions, driving growth on its path to a zero-emission future
• He will also help Ideanomics expand its global talent pool to further develop its key advantage as a global provider of EV mobility solutions
• Mackie brings a wealth of knowledge and decades of experience in the EV sector

On September 8, 2021, Ideanomics (NASDAQ: IDEX) announced the appointment of Robin Mackie as the new President of Ideanomics Mobility. Before he was appointed President, Mr. Mackie served as a consultant for the company for six months, proving his value to its growth and achieving its set goals and objectives (https://ibn.fm/x6i7u). When making the announcement, Alf Poor, the Chief Executive Officer (“CEO”) of Ideanomics, noted: “Robin has proven to be a driving force in his recent consulting role for Ideanomics Mobility. Bringing him onto our internal team in a leadership capacity will help us to expand our already impressive global talent pool, as well as help us further develop our strategic advantage as a global provider of EV mobility solutions.” Mr. Mackie brings over three decades of experience in engineering, operations, and global design in different highly regulated industries, including offshore, construction, and automotive. He has served in different roles, including engineering and development director at Express Group, the President and Chief Technology Officer (“CTO”) of Smith Electric Vehicles, before ultimately starting his consulting business in 2017 (https://ibn.fm/RUN1q). While confirming his appointment, Mr. Mackie noted: “Throughout my more than 30 years in business, I have worked with mobility companies around the globe, and I am thrilled to bring my knowledge and experience to the team at Ideanomics. I am passionate about energy, sustainability, and transportation, all which combine to make this a perfect fit as I step in to lead this division during a period of unprecedented growth for both Ideanomics and the EV industry as a whole.” Ideanomics Mobility is a division of the parent company that offers access to industry-leading products and services across vehicle procurement, charging infrastructure, and energy management, primarily through a suite of EV-specific subsidiaries. This division has landed over $1 billion in acquisitions in the past year alone, including VIA Motors’ proposed acquisition for up to $620 million. It is acquisitions such as these that allow Ideanomics Mobility to offer unrivaled services in the industry. Having Mr. Mackie on board would allow the company to make the most out of these attainments, realize its potential and drive growth on its path to a zero-emission future. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• The company will be utilizing Amazon’s fulfillment services, customer service, and network of affiliates in the U.S. and Canada
• The Amazon platform will also feature PlantX-label plant-based brands and products for sale
• The overall PlantX platform features a one-stop shop for all things plant-based, including grocery, meal delivery, The Plant Shop, weekly recipes, and more
• The company is preparing to begin NCIB on or around September 15, 2021, through September 14, 2022. The shares represent approximately 5% (6,071,757) of the common shares available for purchase.
• Through PI Financial Corp., the company will make the purchase of the common shares for cancelation as they feel their value as a company is underrepresented based on these shares
• An additional purchase of common shares is expected to be initiated by Executive Chairman Fred Leigh up to 5% of the common share available

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) is moving closer to redefining the plant-based community by becoming the most trusted and convenient destination online for people living plant-based lives. PlantX has recently announced that it will be launching as a Seller on the Amazon Marketplace. The company will launch both Canadian and U.S. online stores, list and sell plant-based products, and fulfill customer orders. This strategic e-commerce maneuver will allow PlantX to utilize Amazon’s fulfillment services, customer service, and network of affiliates (https://ibn.fm/Vtt0M). “Launching on the Amazon platform is a great opportunity to boost access to our plant-based brands and products. We are particularly excited about adding PlantX private label products to this new platform,” PlantX Founder Sean Dollinger said. “We believe it will increase our impact as we expand our in-house brands.” PlantX’s platform is positioned to serve as the digital face of the plant-based community, providing a one-stop-shop for everything “plant,” including an easy-to-use e-commerce experience that features:

• Plant-based grocery items – from pantry needs to vitamins, cosmetics, pet food, and more
• Meal delivery with recipes from renowned plant-based chefs from around the world
• The Plant Shop – delivering indoor, household plants to homes across Canada and the US
• Weekly, easy-to-follow plant-based recipes
• Partnerships with restaurants, nutritionists, chefs, and other brands
• Access to a community of like-minded individuals

In addition to the online presence, PlantX connects with consumers through the brick-and-mortar store locations and home delivery – primarily focuses on consumer-packaged goods (“CPGs”) with plant-based opportunities. The company is also planning to commence a normal course issuer bid (“NCIB”). An NCIB is a strategic move where a company purchases a percentage of its issued and outstanding common shares. In the case of PlantX, the company plans to purchase the equivalent of 5% (6,071,757) of the available common shares because it believes that the market price may not fully reflect the underlying value of the business or its future prospects. PlantX believes purchasing and canceling these common shares is an appropriate use of financial resources that will ultimately enhance shareholder value (https://ibn.fm/jW8QQ). In addition to the company’s common stock purchase, Executive Chairman Fred Leigh also intends to purchase up to 5% of PlantX’s issued and outstanding common shares on the open market through the CSE facilities.  PlantX’s NCIB is expected to take place on or around September 15, 2021, terminating on or around September 14, 2022, with all common shares purchased under the NCIB on the open market through the CSE. PlantX plans to execute the plan through PI Financial Corp., a broker it has enlisted to handle the NCIB on behalf of the company. Every common share purchased will be done so for cancellation. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• U.S.-based FingerMotion is a mobile phone services and emerging big data technology company focused on the enormous prospects of China’s marketplace
• FingerMotion’s drive to develop its new Sapientus database IP has led to a significant agreement for providing big data to global insurance juggernaut Pacific Life’s Reinsurance division
• Pacific Life is among a number of outsider companies looking to enter China’s marketplace, and FingerMotion’s data is expected to help the company establish risk prediction profiles for its clientele
• China boasts a population of about 1.4 billion people, of whom more than half have adopted mobile phone technology during the past quarter century as the country’s economy has made great strides forward
• An estimated 989 million Chinese citizens have adopted Internet use and e-commerce as a part of their lifestyle

Given current estimates that China’s population will surpass 1.4 billion people this year, occupying a land mass larger than the United States while building one of the world’s fastest growing economies, it’s no surprise that China has repeatedly occupied a position as the most attractive marketplace in the world during recent years (https://ibn.fm/aswHa). Corporations developing their growth strategies continually freshen their outlooks on the benefits of entering China’s market while weighing any challenges that might be unique to the country, particularly in terms of technological development. But great leaps in Internet and satellite-based communications within the country are helping to drive new confidence in the potential for consumer acquisition and responsiveness. Of note, China’s mobile phone users have increased during the past quarter century from about 3.6 million people to about 986 million, or more than half the country (https://ibn.fm/Kg4tm),  while Internet users have increased from 60,000 people to 989 million (https://ibn.fm/jq2Qc). Evolving technological services company FingerMotion (OTCQX: FNGR) is focused on the development and monetization of communications-related services in China, particularly in exploring the potential of big data and analytical technology to help other companies thrive in the country’s economy. FingerMotion is a U.S.-based company is building a communications ecosystem of active users based on its flagship Sapientus database IP, a predictive services solution that has led to a landmark agreement with Pacific Life Re-insurance as the world-leading insurance juggernaut adds Chinese clients’ needs to its operational infrastructure. FingerMotion anticipates that it may eventually use Sapientus’ capabilities to provide solutions for other market sectors as well, including predictive risk assessments for health care, financial services and consumer e-commerce applications. In June, CEO Martin Shen noted that the relatively new establishment of the company’s Big Data Insights division led to its first revenues during the previous fiscal year and expectations of greater profits during the current year. “We are a technology company and believe our future lies in the Big Data Insights division. By the end of calendar 2021, we expect multiple contracts relating to our Insuretech products,” he reported (https://ibn.fm/matjH). Shen said the company also believes it has taken significant steps toward meeting the qualifications for listing with senior exchanges as its shareholder equity continues to show a healthy response, ending the previous year at $2.11 million. Mobile payment and recharge platform solutions, where its core competency lies, has boosted the company to a level where it handles over 500,000 transactions every day for those services. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Flora also recently announced it had received its 2021 commercial export quota allocation of 7,900 kilograms to cultivate, process, and distribute high-THC cannabis
• Flora Growth also announced it has entered into an agreement with Applied DNA Sciences, Inc. and TruTrace Technologies, Inc.
• FLGC will deploy the two companies’ integrated technology as part of its global cannabis product validation and authentication platform
• The integrated technology will tag, test, and track Flora’s cannabis and cannabis derivative products during transit across an international supply chain, providing enhanced transparency, traceability, and trust

As an internationally focused company, Flora Growth (NASDAQ: FLGC) has always strived to build a global cannabis consumer packaged goods (“CPG”) portfolio by leveraging natural, low-cost cultivation practices; developing products that positively impact the health and wellness of people; and growing a global footprint through partnerships, investments, and acquisitions. In line with this commitment, Flora recently entered into distribution agreements with Kiricann (https://ibn.fm/Q8K4e) and Evergreen Pharmacare (https://ibn.fm/whN6l) to supply dried flower and derivatives to Africa and the EU, as well as Australia, adding to its existing strategic global growth and distribution initiatives. Coming shortly after the Colombian government announced reformed, more accessible cannabis legislation, Flora recently announced it had received its 2021 export quota from the Columbian Technical Quotas Group (“TQG”) to cultivate, process, and distribute up to 7,900 kilograms of high-THC cannabis dried flower (https://ibn.fm/f1Ftj). The company believes the allocated export quota will be sufficient to meet the international demand for its product throughout the remainder of the year and the beginning of 2022. This export quota allocation, coupled with the distribution agreements with Kiricann and Evergreen and the €2 million investment in Hoshi International, closed August 24 (https://ibn.fm/hbCNN), is a significant milestone for the company. According to Warnock, it represents a major opportunity to export Flora’s high-margin, high-THC goods to legal markets around the world. Nonetheless, Flora is not just prioritizing planting the new high-THC cultivars but is also actively harvesting its high-CBD crops, with the harvest expected to create a robust pipeline of cannabis derivatives for the company to use across its premium brands and products, as well as for export. As part of the preparations towards the expected export of cannabis and cannabis products via the two distributors, Flora announced September 8 that it has partnered with Applied DNA Sciences, Inc. (NASDAQ: APDN) and TruTrace Technologies, Inc. (OTC: TTTSF) with the aim of establishing a new global standard for cannabis distribution practices (https://ibn.fm/bieU8). Under the terms of the Master Services Agreement (“MSA”), Flora will deploy an integrated technology that brings together Applied DNA’s CertainT(R) and TruTrace’s StrainSecure(TM) platforms as part of its global cannabis product validation and authentication platform. The integrated technology, which is the result of an agreement between APDN and TruTrace signed earlier this year (https://ibn.fm/2p1XY), will allow Flora’s cannabis and cannabis derivative products to be tagged with a unique molecular identifier and tested for the identifier’s presence during travels across an international supply chain using CertainT. The products will then be tracked using StrainSecure by uploading the data points collected through tagging and testing to a blockchain-based cloud database (https://ibn.fm/EwBld). “In today’s globalized market, supply chain provenance is becoming an increasingly important component for every major CPG company. This is particularly true for the cannabis industry, where concerns over the sale and distribution of products from the illicit market persist for businesses,” said Flora Growth’s Chief Revenue Officer, Jason Warnock. “Flora anticipates that the added assurance, efficiency, and transparency brought by these technologies will optimize our value proposition to customers, differentiate us from peers, and increase our sales opportunities.” According to Applied DNA and TruTrace, the integrated technology will provide enhanced transparency, traceability, and trust across Flora’s international supply chain and will be instrumental in today’s cannabis industry, currently seeking legitimacy as it gains global acceptance. The integrated technology, whose build-out is well underway, will ensure that the products supplied from Colombia and delivered to global customers are derived directly from Flora’s operations. The implementation will, therefore, significantly reduce any concerns regarding illicit market products or counterfeits. Flora’s management anticipates that the integration will be ready in time for use by global customers receiving products, such as Kiricann and Evergreen. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• AmpliTech Group Inc. was recently featured in a Simply Wall Street article that observed multiple instances of insider buying
• Insider buying demonstrates that insiders believe in the company and anticipate the value of its shares will increase
• AmpliTech received two follow-on orders in June and July and reported a 117% quarter-over-quarter revenue increase in Q2 2021
• The company is making strategic investments to position it for hyper-growth opportunities across several markets

A recent Simply Wall Street article on AmpliTech Group (NASDAQ: AMPG) observed that in the last 12 months, multiple insiders acquired the company’s stock in large numbers – but did not sell (https://ibn.fm/rM7mU). Known as insider buying, this practice typically demonstrates that insiders – people with inside knowledge of a public company – believe in the organization and anticipate the share’s value will increase. The article came just a few days after AmpliTech released financial results for the second quarter and the first six months of 2021. The results, along with crucial developments throughout the last year, suggest the factors that could spawn the expected increase in value. A company that designs, develops, and manufactures custom radio frequency components for different markets, AmpliTech was founded in 2002 by president and CEO Fawad Maqbool. Since then, it has built a strong reputation anchored on performance and quality and embodied by recent achievements. On February 17 this year, for instance, the company’s common stock commenced trading on NASDAQ in what the company’s website notes “will help take our products to a broader and more global customer base, bringing cutting-edge technology to the masses and improving everyday quality of life for us all” (https://ibn.fm/GVleu). Even so, the company is already enjoying long-term relationships with several global customers. On July 29, AmpliTech secured $0.5 million in follow-on orders for custom Low Noise Amplifiers (“LNAs”) for a global high-speed satellite broadband services provider. According to Maqbool, the customer recognizes the value of AmpliTech’s industry-leading performance and reliability to deliver data and communications unimpacted by environmental interference (https://ibn.fm/CsvDi). This order came a little over a month after it had announced June 24 a similar follow-on order for its LNA technology from a Fortune 500 global defense and aerospace customer (https://ibn.fm/QH8Fv). Following the June 24 announcement, Maqbool expressed pride in the fact that AmpliTech’s performance, quality, and return on investment of its solutions continued to earn repeat business from global leaders. Further, AMPG’s focus on quality has also seen it garner numerous Supplier Quality awards, including a Best Technology Award from one of the industry’s leading trade magazines. The company anticipates growing business activity as well as increased customer demand as the economy reopens. Already, according to Maqbool, the gradual return of customer prospects has had a positive effect on the company’s financials. “Our Q2 results reflect initial benefits of our significantly enhanced financial position and the gradual return of customer prospects to more normal planning and procurement activity for projects where our low noise amplifier solutions can deliver game-changing performance and ROI,” he stated. For the three months ended June 30, 2021, AmpliTech reported $1.02 million in revenue, up from $660,699 reported in Q2 2020, representing a 55% increase. It also increased 117% when compared to Q1 2021 results. Gross profit increased 52.5% to $344,623 in Q2 2021 up from $225,998 in Q2 2020, reflecting the increase in revenue (https://ibn.fm/qLzpB). According to Maqbool, the company is making strategic investments in product development, sales and marketing, and personnel and infrastructure to better position AmpliTech for hyper-growth opportunities seen across several markets, including the build-out of true 5G infrastructure, quantum computing, space exploration, and satellite communications (SATCOM). Grandviewresearch anticipates that the SATCOM market, estimated at $66.63 billion in 2020, will grow at a 9.8% CAGR from 2021 to 2028 to reach $137.63 billion (https://ibn.fm/nDH70).  It also projects that the global 5G infrastructure market, valued at $2.64 billion in 2020, will grow at a 49.8% CAGR from 2021 to 2028 (https://ibn.fm/OUtRD). The global quantum computing market is expected to grow from $472 million in 2021 to $1.77 billion in 2026, marking a 30.2% CAGR (https://ibn.fm/OHiFK). This projection is based on analysis by MarketsandMarkets, which has also published numerous market reports showing that multiple segments of the space exploration market will experience more than 15% CAGR during the forecast periods, which run until the mid-2020s (https://ibn.fm/iki3X). “AmpliTech has a rich history in the design of microwave amplifiers and components, including a wide variety of product lines, from LNAs and MPAs (Medium Power Amplifiers) to broadband telecom amplifiers for the microwave and fiber optic communication firms,” reads the company’s website. For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

• Canada-based life sciences company Mind Cure Health is developing a synthetic form of the psychedelic drug ibogaine as part of its efforts to take a leading position in the burgeoning market for mental health therapies
• Psychedelics, strengthened by new clinical research driving scientific and legislative openness to the drugs’ possible benefits under controlled conditions, are overcoming stigmas   that arose from recreational use of the drug
• Mind Cure Health is developing a proprietary software-as-a-service (SaaS) platform known as iSTRYM to optimize the healing journey between patients and caregivers
• The company recently released its year-end financial report and an analysis outlining its activities as well as its renewed strategic focus on technology and research

Life sciences company Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) recently reported its financial results for the three and twelve months ended May 31, reporting on its first full year of operations since incorporation in March 2020. The report notes the company’s milestones leading to provisional patent filings for its innovative software application that will be used to provide real-time data for patient care in harmony with Mind Cure’s focus on developing mental health solutions that use novel psychedelic therapies. “The strategy and infrastructure we have put in place over the past year positions the company well to continue the development and release of our digital therapeutics platform, iSTRYM, and to continue our research for psychedelics,” President and CEO Kelsey Ramsden said about the results (https://ibn.fm/z6tz8). “I would like to especially thank our investors for seeing and supporting the vision and execution at MINDCURE.” The company initially began the year developing a nootropic line of functional mushrooms and supplements, in line with the rising consumer use of cognitive enhancement nootropics to improve brain function (https://ibn.fm/qlH35). With the company’s renewed focus on its digital technology and research and development activities, MINDCURE announced in August it has discontinued the development of its nootropics line of products. “As our organization has grown and our bi-divisional technology and drug research strategy have been refined, we need to focus entirely on what we do best – creating advanced and proprietary technology for and drug research in psychedelics,” said Kelsey Ramsden. During the past decade, scientific research and promising clinical trials have begun to suggest that drugs such as LSD, magic mushrooms, DMT, a variety of “plant medicines” including ayahuasca, iboga, salvia and peyote, as well as related compounds like MDMA and ketamine may become recognized as game-changing ways to treat depression, PTSD and addiction. The mental health community has observed the research with enthusiasm (https://ibn.fm/4RxVL). Investors who no longer regard the cannabis industry as a risky pursuit are now moving smart capital behind psychedelics as the “next frontier” of therapeutic solutions. A recent report by Fortune magazine noted that when psychedelic medicine developer ATAI Life Sciences made its recent debut on the Nasdaq, shares surged by 40 percent on the first day of trading, driving the company to a valuation of $2.6 billion. The growing global need for effective mental health treatments, evolving legislation and regulation, and widely supportive public opinion are all helping to drive an increase in investment capital and creating projections that the psychedelic health care market could reach $10.75 billion in revenues by 2027, according to Fortune’s report (https://ibn.fm/TLMdk). Mind Cure’s devotion to building access to safe, science-based, evidence-backed psychedelic-assisted therapies globally includes a provisional patent application for its pharmaceutical-grade synthetic ibogaine to be used in clinical research as the industry advances. For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• Hearing aids are prohibitively expensive for millions of Americans due to market concentration and the requirement that people must see a medical professional before purchasing hearing aids
• INND’s marketing strategy brings the “Direct to Consumer” model to the hearing aid market amid growing recognition that the current traditional model may not be sustainable
• Matthew Moore, company’s CEO, was featured on New to the Street, explaining how the company is committed to helping people get the hearing aids they need at significantly lower costs

In a recent feature on New to the Street, Matthew Moore, InnerScope Hearing Technologies (OTC: INND)’s CEO, informed the audience how the company remains committed to change the lives of millions of Americans with hearing impairment, helping them get the hearing aids they need at a fraction of the cost compared to the traditional hearing healthcare clinics (https://ibn.fm/SIEq7). Although 48 million Americans suffer from hearing loss, the market appears notoriously underserved. The price of hearing aids, which for many is a medical necessity, is so steep that only 14% of people with hearing problems use them (https://ibn.fm/KRynJ), which created the UnderServerd Hearing Aid Market.  For millions of Americans and their families, quality of life can be severely impacted, as hearing impairment can often lead to new health issues, including early onset of dementia. The costs of one hearing aid alone can range from $1,000 to as much as $6,000, that’s usually not including additional expenses that can occur, such as hearing tests, follow-ups, and ongoing support from healthcare professionals (https://ibn.fm/2NmjN). As those costs are often not covered by health insurance, it is no surprise that many people forego getting hearing aids. One of the key drivers of these prohibitive costs keeping the millions of Americans from getting the necessary hearing help is that consumers must get them from a doctor or a specialist, a major barrier that prevents competition and keeps hearing aids extremely expensive. For example, the four largest hearing aid manufacturers control 84% of the global hearing aid market. InnerScope Hearing Technologies is positioned and poised to disrupt the traditional hearing aid market model and bring hearing aid devices straight to consumers’ by shifting hearing care out of the clinics to online, shipping directly to consumers homes or, through an instore model using InnerScope’s innovative point of sale Hearing Screening Kiosks, located in large retail chains and pharmacy chains. As a result, InnerScope is emerging as a disruptive leader in the so-called “Direct-to-Consumer Hearing Technology Market.” In a recent feature on New to the Street, Matthew Moore, InnerScope’s CEO, explained how the company’s marketing strategy is centered around helping people get the hearing aids they need, selling at a fraction of the cost of those sold by the major competitors. Given the lack of Medicare and private insurance coverages or limited coverage on hearing aid devices, InnerScope makes it possible even for those with limited budgets to buy superior quality hearing aids directly for as little as $44 per month (from the company’s website). In addition, InnerScope recently launched its hearing aids and related hearing products on FSAstore.com, HSAstore.com, and WellDeservedHealth.com, for the 70 million consumers enrolled in flexible spending accounts (“FSA”), health saving accounts (“HSA”), and employers’ health incentive programs. For more information, visit the company’s website at www.INND.com and the company’s e-commerce website: www.MyHearIQ.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• Lexaria has begun the formal process of preparing an application for Investigational New Drug status for DehydraTECH(TM) and cannabidiol for hypertension
• The filing is being done with the assistance of an outside consultancy group, with Lexaria Bioscience designing non-clinical, clinical, and related product development required prior to the filing – all of which support Lexaria’s more ambitious goals
• There have been two successful human hypertension trials done with the combination DehydraTECH-CBD therapy in 2021, following an original human clinical study in 2018, and many animal studies
• Lexaria is making a strong case to support the efficacy of the technology for treating hypertension

Lexaria Bioscience (NASDAQ: LEXX), a global innovator currently enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs, is announcing that it has begun the formal process of preparing for Investigational New Drug (“IND”) certification with the US Food and Drug Administration (“FDA”). The IND will be for the company’s patented DehydraTECH-processed cannabidiol (“CBD”) as a prospective registered pharmaceutical treatment for high blood pressure (hypertension) (https://ibn.fm/wGUMq). With the help of an expert regulatory affairs and quality assurance consultancy group, Lexaria has begun preparations for a pre-IND meeting with the FDA and designing the non-clinical, clinical, and related product development IND-enabling work that must be completed prior to the IND filing. The IND-enabling program is being made possible by successfully completing studies supporting the company’s more ambitious goals. The company recently achieved results from two successful human clinical pharmacodynamic hypertension studies done in 2021. In addition to the human pharmacokinetic study in 2018 and successful animal studies proving the performance and molecular characterization work through Canada’s National Research Council, Lexaria provides a strong case with supporting bodies of evidence for the DehydraTECH-CBD combination. The studies have shown that DehydraTECH-CBD provides superior bioabsorption upon administration orally and the efficacy of reducing blood pressure without the presence of significant side effects. The IND application is also expected to use data from the company’s third and fourth 2021 human clinical hypertension studies. Lexaria hopes to contribute further data to the growing package of information. Provided that the studies continue with favorable outcomes, the company plans to file the IND at the appropriate time and possibly through an abbreviated 505(b)(2) pathway. Lexaria specifically designed DehydraTECH to formulate and deliver lipophilic (fat-soluble) drugs and other active ingredients. The major benefits assigned to ingesting a DehydraTECH-enabled drug includes:

• Speeding up the delivery of the drug – effects may be felt in a matter of minutes
• An increase in bioavailability – more effective at delivering compounds into the bloodstream
• An increase in brain absorption – animal testing has suggested a significant improvement in the quantity of the DehydraTECH-enabled drug across the blood-brain barrier
• Increased potency – more of the ingested product is made available to the body requiring lower doses to be administered
• Lower drug administration costs – lower dosages equate to lower administration costs
• Covering up the unfavorable taste – the technology eliminates or reduces the need for additional sweeteners

Through animal studies, Lexaria has demonstrated that the quantity of DehydraTECH-enabled drugs across the blood-brain barrier is elevated to as much as 1,900 percent. This finding has enabled the company to initiate new patent applications and opens possibilities for improved drug delivery across the board. Lexaria began developing DehydraTECH in 2014 and has since been working through a collective research agreement with the National Research Council. DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspension. Protective patents have been filed for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (brand names like Viagra), tobacco, and more. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Despite the challenges posed by the COVID pandemic during the past year and a half, music artists have continued producing content and fans have increased their efforts to connect with that content
• Analysts forecast that in the larger entertainment streaming industry, market revenues will grow from the $50 billion recorded early last year to $240 billion by the end of the decade
• Entertainment technology innovator Friendable Inc. has built a platform to capture a share of the streaming market for music artists, helping artists build their own brands and monetize their performances and content in turn
• While the pandemic is widely viewed as the impetus for the astronomical growth of the streaming industry, analysts anticipate the growth trend will continue well beyond the end of the pandemic
• Fan Pass has signed thousands of artists to the platform during the past year, welcoming independent as well as more established artists in an open market opportunity that costs viewers only a few dollars a month

The rapid upscaling of the streaming subscriber market during the ongoing COVID pandemic has now become a pivot point for major companies anticipating that the pandemic will end but the livestream model will continue onward. The merged Warner Bros. Discovery brand’s recent declaration that its existing and planned content is popular enough to drive ongoing revenues through subscriptions despite the consumer trend toward cord-cutting highlights business directives outlined by a multitude of other services in the realm such as Disney+, Paramount Plus and Netflix (https://ibn.fm/0TQIP). Telemedia Online reported Sept. 13 that the video streaming market is expected to grow from the $50 billion revenue mark it posted in early 2020 to “a whopping $240 billion by 2030” with a CAGR in excess of 21 percent as consumers seek entertainment beyond the large original content creators, increasing their use of all major platforms, including social media sites like Instagram and YouTube as working from home also becomes a more common part of their daily lives (https://ibn.fm/Yn96Z). As part of this societal trend groundswell, marketing and mobile entertainment technology innovator Friendable (OTC: FDBL) has pivoted its operating model for building connections between people, working to sell off its once-flagship dating app while turning its attentions toward an emerging platform for driving multi-faceted networking between music artists and their fan consumers. Friendable is nearing the end of a 120-day buildup strategy for the company, launching version 2 of its Fan Pass mobile and web applications with new tech tools to help artists boost their personal brand, increasing public media campaigns, and adding industry talents, partners and BOD support, among other things (https://ibn.fm/6hwin). The company was founded by brothers Robert A. Rositano Jr. and Dean Rositano, who have decades of experience working together on technology-related ventures and a background in the music performance industry. “We had started working on Fan Pass years ago as we started Friendable and launched the company with another mass market opportunity in the dating space. We have pivoted as we developed celebrity relationships and other partners in the artist arena,” Robert, the company’s CEO, told SmallCapVoice in a July interview (https://ibn.fm/LhRa0). “From early days … we’ve formed many relationships in the entertainment community and we’ve done various different things in music over our careers, so it’s timely that the pandemic led us back kind of to our roots.” Fan Pass has expanded its offering with Artist Pro, a suite of services designed to help artists earn a living at a time when live performances are affected by public gathering restrictions. Through Fan Pass, artists can monetize their performances online, create and sell customized merchandise, provide fans with opportunities to not only see performances but gain VIP access to select elements of the artists’ events, and take a direct hand in their own brand development. Artist Pro is currently offered at $8.99. “I get these questions as well: ‘Well, what about as the pandemic lifts and the vaccinations become more widespread?’” Robert Rositano Jr. told SmallCapVoice. “Live events are opening back up. Concerts are coming back in play. That’s what Fan Pass was all about to begin with before the pandemic hit. Fan Pass was all about taking behind-the-scenes or backstage experiences and bringing them to a fanbase that is typically global when we look at a music artist. And a lot of these fans are geographically challenged or maybe not financially able to attend the backstage meet and greet.” For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

Date: October 11-12, 2021 Online Livestream Dynamic Global Events (“DGE”) is proud to announce its 2nd Risk Evaluation and Mitigation Strategies (“REMS”) virtual summit. This two-day event, scheduled for October 11-12, 2021, will be an excellent avenue for life science professionals to develop decision making skills to adapt to anticipate FDA feedback with ease. This virtual conference is an exceptional resource for gaining new insights into adapting to risk mitigation strategies regarding submissions and modifications. DGE has partnered with BioMed Wire, Pharma Voice, Pharma Marketing Networks, and FDA News Watch, among other enterprises, to offer a wholesome experience to event attendees. They have also customized the program to also appeal to technology vendors, drug safety service providers, pharmacovigilance or drug surveillance specialists, along with data management service providers. This virtual summit will feature top industry experts from critical industry institutions, including Pfizer, Alexion, Merck, CVS, Amneal Pharmaceuticals, GlaxoSmithKline, and Walgreens. Some of the presenters include Kyle Irwin, Operations Lead REMs at Janssen, Jamie Wilkins, Director, Center of Excellence for Risk Management, Worldwide Safety at Pfizer and formerly of the FDA, Nancy Dubois, Associate Director, US Local Safety Officer at Alexion and more. Participants will have an opportunity to interact with these industry leaders, exchange ideas and insights into REMS compliance along with how to communicate with healthcare professionals (“HCPs”), patients, and pharmacies. With the involvement of key advisors within these industries, DGE has developed an agenda that covers all integral aspects of REMS core competencies.  Some of the challenges that will be addressed are how to monitor for risks of inadequate communications, maintaining compliance and inspection readiness, addressing new barriers facing retail pharmacy and specialty pharmacy, and techniques and technologies for effective REMS drug distribution. To learn more about the event, please visit our page https://ibn.fm/FTSBl If interested in attending this virtual event visit https://ibn.fm/rEhSV